Comparing two drug combos before surgery for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive breast cancer that has not spread to distant organs.
- You have not had surgery, chemotherapy, or targeted therapy for this breast cancer before.
- You are 18 years or older and in generally good health (able to do daily activities).
- Your kidney, liver, and heart function are within certain safe limits.
- You have not had significant nerve damage from other causes.
- You are willing to have a small piece of your stored tumor tissue sent for research.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if a newer drug, Trastuzumab Rezetecan, works as well as an approved drug, Trastuzumab Deruxtecan, when given before surgery for HER2-positive breast cancer. It aims to see which one helps shrink tumors more effectively.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This trial tests a new combination of two targeted drugs (Trastuzumab Rezetecan and Pertuzumab) given before surgery for HER2-positive breast cancer. The goal is to see if this approach shrinks tumors more effectively.
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests two different chemotherapy drugs, lobaplatin or carboplatin, given before surgery to shrink HER2-positive breast tumors. It aims to see which drug works better and is safer for you.
This trial tests a new drug called TQB2102 combined with standard chemotherapy (TCbHP) as a first treatment before surgery for HER2-positive early breast cancer. The goal is to see if this combination works better than the current standard therapy.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.